These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 3076200)
61. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group. Larsen JP; Boas J Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975 [TBL] [Abstract][Full Text] [Related]
62. Pergolide in late-stage Parkinson disease. Lang AE; Quinn N; Brincat S; Marsden CD; Parkes JD Ann Neurol; 1982 Sep; 12(3):243-7. PubMed ID: 6753730 [TBL] [Abstract][Full Text] [Related]
63. Letter: Psychosis in patient on bromocriptine and levodopa with carbidopa. Lipper S Lancet; 1976 Sep; 2(7985):571-2. PubMed ID: 60643 [No Abstract] [Full Text] [Related]
64. [Combined therapy of parkinsonism with bromocriptine, L-dopa and decarboxylase inhibitor (author's transl)]. Vardy J; Rabey JM; Streifler M Harefuah; 1977 Sep; 93(5-6):129-33. PubMed ID: 924233 [No Abstract] [Full Text] [Related]
65. [Effects of simultaneous administration of pyridoxine in the combined administration of L-dopa and peripheral decarboxylase inhibitors. Experimental and clinical studies]. Namba S; Omoto T; Kishikawa H No To Shinkei; 1976 Aug; 28(8):815-22. PubMed ID: 829033 [No Abstract] [Full Text] [Related]
66. Severity of Parkinson's disease and the dosage of bromocriptine. Larsen TA; Newman R; LeWitt P; Calne DB Neurology; 1984 Jun; 34(6):795-7. PubMed ID: 6539444 [TBL] [Abstract][Full Text] [Related]
67. [Clozapine, a valuable contribution for the treatment of psychoses in Parkinson disease]. Andersson U; Freccero-Rosman K; Aquilonius SM; Nylander B; Lindvall O; Odin P Lakartidningen; 1992 Dec; 89(49):4244-6. PubMed ID: 1461047 [No Abstract] [Full Text] [Related]
68. Failure of oral administration of single rising doses of bromocriptine to produce acute anti-Parkinsonian effects. Poewe W; Schelosky L; Kleedorfer B J Neurol Neurosurg Psychiatry; 1991 Feb; 54(2):186-7. PubMed ID: 2019851 [No Abstract] [Full Text] [Related]
69. Decreased efficacy of levodopa with carbidopa in parkinsonian patients after adrenal-to-caudate implants. Tsui JK; Peppard RF; Petruk KC; Allen G; Burns RS; Calne DB Neurology; 1990 May; 40(5):845-6. PubMed ID: 2330116 [TBL] [Abstract][Full Text] [Related]
70. Treatment of Parkinsonian syndrome with dexetimide. Deze J; Völler GW Acta Psychiatr Belg; 1979; 79(6):704-11. PubMed ID: 554448 [TBL] [Abstract][Full Text] [Related]
71. Third interim report of the nationwide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. Nakanishi T; Kanazawa I; Goto I; Iwata M; Kowa H; Mannen T; Mizuno Y; Nishitani H; Ogawa N; Takahashi A Eur Neurol; 1990; 30 Suppl 1():3-8. PubMed ID: 2178938 [TBL] [Abstract][Full Text] [Related]
72. Effect of antacid on levodopa therapy. Lau E; Waterman K; Glover R; Schulzer M; Calne DB Clin Neuropharmacol; 1986; 9(5):477-9. PubMed ID: 3768869 [No Abstract] [Full Text] [Related]
73. A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up. Montastruc JL; Rascol O; Rascol A J Neurol Neurosurg Psychiatry; 1989 Jun; 52(6):773-5. PubMed ID: 2664089 [TBL] [Abstract][Full Text] [Related]
74. Treatment of the on-off syndrome in Parkinsonism with low dose bromocriptine in combination with levodopa. Bateman DN; Coxon A; Legg NJ; Reid JL J Neurol Neurosurg Psychiatry; 1978 Dec; 41(12):1109-13. PubMed ID: 366085 [TBL] [Abstract][Full Text] [Related]